Kallyope nets $236m Series D

Kallyope Inc, a biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, has secured $236 million in Series D financing.

15 February 2022•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles